Griffin Centre Mental Health Services

Belkins
Griffin Centre is an accredited non-profit mental health agency providing flexible and accessible services to youth, adults and their families. Since 1975, Griffin Centre has been delivering services to people who thought their needs didn't count. We continue to expand our programs and services to respond to the changing and emerging needs of diverse individuals in our community. We help them find solutions to their challenges. We help over 2,500 people each year to recognize their strengths, achieve their goals and improve their lives.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CURIS ANNOUNCES $30 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC

BioSpace | February 27, 2020

news image

Curis, Inc. a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30 million with Aspire Capital Fund, LLC ("Aspire Capital"). Under the terms of the Agreement, Aspire Capital has made an initial investment of $3 million via purchase of 2,693,965 common shares of Curis. In addition, Aspire Capital has committed to purchasi...

Read More

TYLIGAND BIOSCIENCE AND CONTEXT THERAPEUTICS SIGN STRATEGIC DEVELOPMENT AGREEMENT FOR ONAPRISTONE ER

BioSpace | March 12, 2020

news image

Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, and Context Therapeutics LLC, a clinical stage biopharmaceutical company focused on hormone driven cancers, today announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). Onapristone ER is currently being evaluated in patients with progesterone receptor positive (PR+) ovarian and endometrial cancers in t...

Read More

INDUSTRIAL IMPACT

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

news image

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More

RESEARCH

ALIVAMAB DISCOVERY SERVICES IS EXPANDING THE DRUG DISCOVERY PLATFORM WITH THE INTRODUCTION OF NEW ANTIBODY ENGINEERING DEPARTMENT

AlivaMab | May 13, 2021

news image

AlivaMab Discovery Services, LLC ("ADS"), a pioneer in the discovery of superior antibody therapeutics, announced today the formation of its new Antibody Engineering Department, headed by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering, bringing 15 years of experience from Macrogenics Inc. in antibody engineering, discovery, and development, MedImmune, LLC/AstraZeneca PLC, Gritstone Bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's expe...

Read More
news image

CURIS ANNOUNCES $30 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC

BioSpace | February 27, 2020

Curis, Inc. a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30 million with Aspire Capital Fund, LLC ("Aspire Capital"). Under the terms of the Agreement, Aspire Capital has made an initial investment of $3 million via purchase of 2,693,965 common shares of Curis. In addition, Aspire Capital has committed to purchasi...

Read More
news image

TYLIGAND BIOSCIENCE AND CONTEXT THERAPEUTICS SIGN STRATEGIC DEVELOPMENT AGREEMENT FOR ONAPRISTONE ER

BioSpace | March 12, 2020

Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, and Context Therapeutics LLC, a clinical stage biopharmaceutical company focused on hormone driven cancers, today announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). Onapristone ER is currently being evaluated in patients with progesterone receptor positive (PR+) ovarian and endometrial cancers in t...

Read More
news image

INDUSTRIAL IMPACT

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More
news image

RESEARCH

ALIVAMAB DISCOVERY SERVICES IS EXPANDING THE DRUG DISCOVERY PLATFORM WITH THE INTRODUCTION OF NEW ANTIBODY ENGINEERING DEPARTMENT

AlivaMab | May 13, 2021

AlivaMab Discovery Services, LLC ("ADS"), a pioneer in the discovery of superior antibody therapeutics, announced today the formation of its new Antibody Engineering Department, headed by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering, bringing 15 years of experience from Macrogenics Inc. in antibody engineering, discovery, and development, MedImmune, LLC/AstraZeneca PLC, Gritstone Bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's expe...

Read More